AEVIS VICTORIA SA / Key word(s): Preliminary Results Ad hoc announcement pursuant to Art. 53 LR Fribourg, 20 March 2023 AEVIS VICTORIA SA (AEVS:SW) – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m) Two weeks before the publication of its Annual Report 2022, AEVIS VICTORIA SA (AEVIS) informs that, with consolidated revenues of more than one billion Swiss francs (CHF 1’144 million), the EBITDA margin and the net result are up sharply, in particular following the normalization of the hotel business. Consolidated EBITDAR (before rent) will exceed CHF 200 million, with an EBITDAR margin over 20%. EBITDA will be between CHF 125 and 130 million, with a margin above 12%. The 2022 net income will exceed CHF 60 million (2021: CHF 4.6m). For further information: AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich AEVIS VICTORIA SA - Investing for a better life AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), the only Swiss private network of hospitals present in the country's three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com. End of Inside Information |
1586121 20-March-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.